Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

SaRNA for protecting myocardial cells from stress injury and application thereof

A cardiomyocyte and stress technology, applied in the field of saRNA, can solve the problems that have not been explored in the cardiovascular field, and achieve the effect of protecting cardiomyocytes from stress damage, strengthening the protective effect of cardiomyocytes, and preventing damage

Pending Publication Date: 2022-01-14
PEKING UNIV +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the role of saRNA in inhibiting tumor growth and promoting tumor cell apoptosis has been reported, but there is still a long way to go before it can be widely used in clinical practice, and more basic research and clinical evidence are needed to support it.
On the other hand, although saRNA technology has made great progress in the field of tumors, it has not yet been explored in the field of cardiovascular disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • SaRNA for protecting myocardial cells from stress injury and application thereof
  • SaRNA for protecting myocardial cells from stress injury and application thereof
  • SaRNA for protecting myocardial cells from stress injury and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1D

[0078] Example 1 Screening of DUSP12 gene saRNA and anti-myocyte hypertrophy effect after preactivation

[0079] Selection of target genes

[0080] Cardiac hypertrophy has become a major public health problem due to high morbidity, severe clinical prognosis, and limited treatment options. According to the reports of existing studies: CCR9 promotes the progression of cardiac hypertrophy by up-regulating the phosphorylation levels of related proteins in the PI3K / AKT pathway in cardiomyocytes; the specific PI3K inhibitor LY294002 also inhibits the activation of AKT mediated by PI3K Progression of cardiac hypertrophy. In addition, the progress of MAPK pathway and NF-κB pathway in regulating cardiac hypertrophy is also based on changes in the cascade phosphorylation of multiple signaling molecules, and the bidirectional interaction between protein kinases and phosphatases plays a very important role in this process. Therefore, this study assumes that by changing the expression l...

Embodiment 2

[0098] Example 2 Screening of HSPA1A gene saRNA and anti-hypoxic damage effect after preactivation

[0099] Selection of target genes

[0100] Coronary atherosclerotic heart disease (Coronary atherosclerotic heart disease, CHD) is a heart disease caused by myocardial ischemia and hypoxia due to coronary atherosclerosis leading to narrowing or obstruction of the coronary lumen. In my country, the incidence of coronary heart disease presents a rapid upward trend, and it has become the largest disease that constitutes the mortality rate of urban and rural residents in my country, seriously endangering the health of the people and causing serious impact on the national economy. However, in stark contrast to the current high morbidity, high prevalence and high mortality are the current limited treatment methods and far from satisfactory treatment effects. The main treatment methods for coronary heart disease include drug therapy, interventional therapy and surgical treatment. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

SaRNA capable of activating myocardial hypertrophy related genes and hypoxia stress related genes is screened, myocardial cells are respectively transfected with the saRNA to activate target gene expression, myocardial hypertrophy stimulation and hypoxia stimulation are respectively given on the basis, it is found that the activated target genes have a good protection effect on cells under stress conditions, and therefore, an effective method is provided for cell protection.

Description

technical field [0001] The present invention relates to a saRNA, a pharmaceutical composition containing the saRNA and their application. Specifically, the present invention relates to a saRNA used to protect cardiomyocytes from stress damage, a pharmaceutical composition containing the saRNA as an active ingredient, and the saRNA and the pharmaceutical composition are used in the preparation of the saRNA to protect cardiomyocytes from stress damage. The application of the saRNA and the pharmaceutical composition to protect cardiomyocytes from stress injury. Background technique [0002] The gene expression silencing phenomenon mediated by double-stranded RNA (double-stranded RNA, dsRNA) is called RNA interference (RNA interference, RNAi). With the deepening of research, the mechanism of RNAi has been gradually elucidated. The exogenously introduced long dsRNA, small hairpin RNA (small hairpin RNA, shRNA) and small interfering RNA (small interfering RNA, siRNA) undergo cer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113A61K48/00A61K31/713A61P9/00A61P9/10
CPCC12N15/113A61K31/713A61P9/00A61P9/10
Inventor 曹慧青许政曦郑哲王晓霞刘汉凝盖书杰
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com